Esophageal cancer screening: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) No edit summary |
No edit summary |
||
| Line 8: | Line 8: | ||
===Adenocarcinoma screening=== | ===Adenocarcinoma screening=== | ||
The predominant type of esophageal cancer in the United States is [[adenocarcinoma]]. | *The predominant type of esophageal cancer in the United States is [[adenocarcinoma]]. | ||
*Screening is recommended for white men over the age of 50 years.<ref name="pmid26185366">{{cite journal |vauthors=Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á |title=Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries |journal=World J. Gastroenterol. |volume=21 |issue=26 |pages=7933–43 |year=2015 |pmid=26185366 |pmc=4499337 |doi=10.3748/wjg.v21.i26.7933 |url=}}</ref> | |||
*Screening should include random endoscopic [[Biopsy|biopsies]] taken in all 4 quadrants with a high resolution [[Endoscopy|endoscope]] once in a lifetime. | |||
*It should also be noted that those who present with [[adenocarcinoma]] demonstrate no prior [[Barrett's esophagus]] in 80 - 90% of the time. | |||
===Squamous cell carcinoma screening=== | ===Squamous cell carcinoma screening=== | ||
[[Squamous cell carcinoma]] of the esophagus is more prevalent in underdeveloped countries; there is no reliable data to suggest that screening programs are effective when implemented. | [[Squamous cell carcinoma]] of the esophagus is more prevalent in underdeveloped countries; there is no reliable data to suggest that screening programs are effective when implemented. | ||
*A screening program in a high risk population was established in Hishun village,China. | |||
*Those with mild to moderate [[dysplasia]] were examined via endoscopy every 3 years, whilst those with severe [[dysplasia]] were screened once per year. | |||
* | *All the patients were concomitantly treated with monoclonal antibodies for the next three years. | ||
*At the end of three year monoclonal antibody trial, the incidence rate of esophageal [[squamous cell carcinoma]] had decreased by 57% in comparison to previous incidence rates. | |||
*These results demonstrated that screening for dysplastic changes in the esophagus is effective in the prevention of esophageal squamous cell carcinoma. <ref name="pmid3219974">{{cite journal |vauthors=Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP |title=[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus] |language=Chinese |journal=Zhonghua Zhong Liu Za Zhi |volume=10 |issue=3 |pages=161–6 |year=1988 |pmid=3219974 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
Revision as of 15:02, 21 December 2017
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer screening On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer screening |
|
Risk calculators and risk factors for Esophageal cancer screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Screening may be effective in reducing the incidence of esophageal cancer, especially in Barrett's esophagus-associated adenocarcinoma, however, not very cost effective.
Screening
Adenocarcinoma screening
- The predominant type of esophageal cancer in the United States is adenocarcinoma.
- Screening is recommended for white men over the age of 50 years.[1]
- Screening should include random endoscopic biopsies taken in all 4 quadrants with a high resolution endoscope once in a lifetime.
- It should also be noted that those who present with adenocarcinoma demonstrate no prior Barrett's esophagus in 80 - 90% of the time.
Squamous cell carcinoma screening
Squamous cell carcinoma of the esophagus is more prevalent in underdeveloped countries; there is no reliable data to suggest that screening programs are effective when implemented.
- A screening program in a high risk population was established in Hishun village,China.
- Those with mild to moderate dysplasia were examined via endoscopy every 3 years, whilst those with severe dysplasia were screened once per year.
- All the patients were concomitantly treated with monoclonal antibodies for the next three years.
- At the end of three year monoclonal antibody trial, the incidence rate of esophageal squamous cell carcinoma had decreased by 57% in comparison to previous incidence rates.
- These results demonstrated that screening for dysplastic changes in the esophagus is effective in the prevention of esophageal squamous cell carcinoma. [2]
References
- ↑ Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á (2015). "Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries". World J. Gastroenterol. 21 (26): 7933–43. doi:10.3748/wjg.v21.i26.7933. PMC 4499337. PMID 26185366.
- ↑ Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP (1988). "[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus]". Zhonghua Zhong Liu Za Zhi (in Chinese). 10 (3): 161–6. PMID 3219974.